Ophthalmology News and Research RSS Feed - Ophthalmology News and Research

Annual diabetic retinopathy screening for children with type 1 diabetes should begin at later age, study says

Annual diabetic retinopathy screening for children with type 1 diabetes should begin at later age, study says

A new study has found that the occurrence of advanced forms of a diabetic eye disease remains low among children living with diabetes, regardless of how long they have had the disease or their ability to keep blood sugar levels controlled. Researchers are therefore recommending that most children with type 1 diabetes delay annual diabetic retinopathy screenings until age 15, or 5 years after their diabetes diagnosis, whichever occurs later. [More]
BioLight Life Sciences Investments reports operational and financial results for Q2 2015

BioLight Life Sciences Investments reports operational and financial results for Q2 2015

BioLight Life Sciences Investments, a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today reported operational and financial results for the second quarter ended June 30, 2015. [More]
Researchers discover that vitamin D may play significant role in preventing AMD among women

Researchers discover that vitamin D may play significant role in preventing AMD among women

Vitamin D has been studied extensively in relation to bone health as well as cancer. Now, a team led by a researcher at the University at Buffalo has discovered that vitamin D may play a significant role in eye health, specifically in the possible prevention of age-related macular degeneration, or AMD, among women who are more genetically prone to developing the sight-damaging disease. [More]
Research with UWF imaging may change how diabetic eye disease is assessed and treated

Research with UWF imaging may change how diabetic eye disease is assessed and treated

For decades, clinicians have detected and monitored diabetic eye disease with standard retinal photographs that cover about a third of the retina. In recent years, an emerging class of ultrawide field (UWF) cameras has given a substantially larger view of the retina, providing new insight on the presentation and natural history of retinal disease. [More]
Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma's total revenue decreases 50% to €1.9 million in second quarter 2015

Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced financial results for the three and six months ended June 30, 2015. [More]
ARVO Foundation for Eye Research to present Dr. David L. Epstein Award at ARVO 2016

ARVO Foundation for Eye Research to present Dr. David L. Epstein Award at ARVO 2016

To honor the memory of a longtime leader in glaucoma treatment and research, the ARVO Foundation for Eye Research will present the Dr. David L. Epstein Award. The new award — a $100,000 prize — was established by the late Dr. Epstein's family and will be presented annually to a senior-level glaucoma researcher at the ARVO Annual Meeting. [More]
STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

STA inks license and commercialisation agreement with PharmaMar for APLIDIN (plitidepsin)

Australian biopharmaceutical company Specialised Therapeutics Australia has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN (plitidepsin) in Australia and New Zealand. [More]
Johns Hopkins scientists develop novel fish embryo technique to identify potential new treatments for diabetes

Johns Hopkins scientists develop novel fish embryo technique to identify potential new treatments for diabetes

In experiments with 500,000 genetically engineered zebrafish embryos, Johns Hopkins scientists report they have developed a potentially better and more accurate way to screen for useful drugs, and they have used it to identify 24 drug candidates that increase the number of insulin-producing cells in the pancreas. [More]
Tracking retinal changes may help doctors to adjust schizophrenia treatment in the future

Tracking retinal changes may help doctors to adjust schizophrenia treatment in the future

Schizophrenia is associated with structural and functional alterations of the visual system, including specific structural changes in the eye. Tracking such changes may provide new measures of risk for, and progression of the disease, according to a literature review published online in the journal Schizophrenia Research: Cognition, authored by researchers at New York Eye and Ear Infirmary of Mount Sinai and Rutgers University. [More]
Risk for endophthalmitis no higher with Avastin, finds study

Risk for endophthalmitis no higher with Avastin, finds study

Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug Lucentis made by the same company, according to new research from the Perelman School of Medicine at the University of Pennsylvania. Their findings are published today in JAMA Ophthalmology. [More]
Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand Imprimis' proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada. [More]
Scientists identify molecular pathway that can contribute to vision loss in macular degeneration

Scientists identify molecular pathway that can contribute to vision loss in macular degeneration

Scientists have identified a pathway that leads to the formation of atypical blood vessels that can cause blindness in people with age-related macular degeneration. [More]
Roche establishes strategic alliance with Diagnostic Laboratory Services

Roche establishes strategic alliance with Diagnostic Laboratory Services

Roche announced today the establishment of a strategic alliance with Diagnostic Laboratory Services of Aiea, Hawaii, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years. [More]
Pennsylvania physicians examine back-to-school health, offer tips for parents and students

Pennsylvania physicians examine back-to-school health, offer tips for parents and students

As students start heading back to classes for the upcoming academic year, Pennsylvania physicians take a close look at back-to-school health and offer some tips for parents and students who strive to stay in class and not home in bed sick. [More]
Shire acquires Foresight Biotherapeutics for $300 million

Shire acquires Foresight Biotherapeutics for $300 million

Shire plc announced today that it has acquired New York-based, privately held Foresight Biotherapeutics Inc. for $300 million. [More]
Omeros receives EC approval to market Omidria in EU and other European countries

Omeros receives EC approval to market Omidria in EU and other European countries

Omeros Corporation today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in the European Union (EU) for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. [More]
Researchers reconstruct ancient virus to improve gene therapy

Researchers reconstruct ancient virus to improve gene therapy

Researchers at Massachusetts Eye and Ear/Schepens Eye Research Institute have reconstructed an ancient virus that is highly effective at delivering gene therapies to the liver, muscle, and retina. This discovery, published July 30 in Cell Reports, could potentially be used to design gene therapies that are not only safer and more potent than therapies currently available, but may also help a greater number of patients. [More]
Roche submits cobas EGFR v2 test PMA to FDA as companion diagnostic test for AZD9291

Roche submits cobas EGFR v2 test PMA to FDA as companion diagnostic test for AZD9291

Roche today announced it has submitted the cobas EGFR Mutation Test v2 for Premarket Approval (PMA) to the U.S. Food and Drug Administration, as a companion diagnostic test for AZD9291, an AstraZeneca investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation. [More]
CMC Biologics, River Vision sign manufacturing agreement for Teprotumumab to treat Grave's Orbitopathy

CMC Biologics, River Vision sign manufacturing agreement for Teprotumumab to treat Grave's Orbitopathy

CMC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and River Vision Development Corporation (River Vision), a private company focused on ophthalmology, announced today that they have entered into an agreement for the process transfer and cGMP production of RV001 (Teprotumumab) – a recombinant monoclonal antibody targeting insulin-like growth factor 1 that is in development for treatment of Grave's Orbitopathy and other indications. [More]
Study explores better treatment options for patients with optic disc pits

Study explores better treatment options for patients with optic disc pits

New research from the University of Alberta's Faculty of Medicine & Dentistry is showing less is more when it comes to the treatment of optic disc pits--a rare eye condition. [More]
Advertisement
Advertisement